Navigation Links
Market testing of dietary supplements and drugs underscores value of USP's public health programs
Date:11/12/2007

Rockville, Md., November 12, 2007 On September 10, 2007, ConsumerLab.com issued a report stating that several multivitamin supplements did not contain label amounts of folic acid. One of these products, B-50 Tablets, manufactured by IVC, Industries, Inc., is part of U. S. Pharmacopeias (USP) Dietary Supplement Verification Program and carries the USP Verified mark. In response to the report, USP studied the verified product to confirm the announced results. USPs testing found that the B-50 Tablets do in fact contain the required amount of folic acid, as claimed on the products label. The testing also demonstrated that the tablet in question meets USP dissolution requirements. USPs analysis showed that using appropriate test methods for the type of material under assessment, as provided in the United States Pharmacopeia and National Formulary (USPNF), is key to getting accurate results.

The importance of ongoing testing of dietary supplements to a public monograph is hard to overstate, said Roger L. Williams, M.D., executive vice president and CEO of USP. For this reason, USP acknowledges ConsumerLab.coms marketplace surveillance efforts. At the same time, these efforts require careful follow-up, which USP was able to do via its USP Verified agreement with the manufacturer of the B-50 Tablets. USP understands that further studies may be conducted by manufacturers and the Food and Drug Administration (FDA) based on the September 10 report.

The USP Verified program for dietary supplements and their ingredients provides a rigorous array of tests, resulting in manufacturer and consumer confidence that whats on the label is whats in the bottle. Via its voluntary, fee-based agreements with manufacturers, USP has a continuing commitment to monitor the quality of verified ingredients and products. USP was pleased to be able to clarify some of the findings of ConsumerLab.com.

In a separate report dated October 12, 2007, ConsumerLab.com called into question the therapeutic interchangeability of two marketed extended release formulations of Buproprion Hydrochoride. For these drugs, primary responsibility for original and continuing market availability rests with the FDA working with manufacturers. USP notes that it does have drug product monographs for the involved formulations in the United States Pharmacopeia and that these monographs allow different dissolution requirements. This is appropriate on the assumption that the FDA has reviewed and found acceptable bioequivalence studies for formulations conforming to the monographs. USP does not verify drug products approved by the FDA.


'/>"/>

Contact: Sandra Kim
sek@usp.org
301-816-8241
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Emerging (disease) markets
3. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
4. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
5. Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels
6. Safe water: simpler method for analyzing radium in water samples cuts testing time
7. Genetic ancestral testing cannot deliver on its promise, study warns
8. ACT Ensures Integrity of Testing Process Through Deployment of BIO-keys(R) Biometric ID Technology
9. UF scientists reveal how dietary restriction cleans cells
10. Dietary calcium could possibly prevent the spread of breast cancer to bone
11. Changing the global dietary environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... DIEGO , March 29, 2017  Halozyme ... novel oncology and drug-delivery therapies, today announced that ... Food and Drug Administration voted 11 to 0 ... the skin) injection was favorable for patients in ... B-cell lymphoma and chronic lymphocytic leukemia. The FDA ...
(Date:3/29/2017)... ... 29, 2017 , ... Bactana Animal Health, a company developing natural products aimed ... enhancement of the gut microbiota, today announced the closing of its first round of ... Sustainable Income Capital Management, LLC and a number of private investors. The company will ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or ... a new risk stratification test for breast cancer, via its ... Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with a ... for developing breast cancer.   ... BreastSentry measures the fasting plasma levels ...
(Date:3/28/2017)... Hong Kong (PRWEB) , ... March 28, 2017 ... ... has selected NetDimensions Learning to replace paper-based processes and enhance training plan management ... “We are very pleased to partner with the SHL Group to help improve ...
Breaking Biology Technology: